Intensity Therapeutics logo
INTSIntensity Therapeutics
Trade INTS now
Intensity Therapeutics primary media

About Intensity Therapeutics

Intensity Therapeutics (NASDAQ:INTS) is a biotech firm deeply engaged in the development of immunotherapy treatments aimed at a variety of cancers. The company's unique approach involves directly injecting its drug candidates into solid tumors to stimulate an immune response that targets cancer cells throughout the body. Among its notable projects is INT230-6, designed to improve the effectiveness of existing cancer therapies and reduce their side effects. Intensity Therapeutics is keen on transforming cancer treatment by fostering durable responses in advanced and hard-to-treat cancers, demonstrating its commitment to changing the landscape of cancer care through innovation and research.

What is INTS known for?

Snapshot

Public US
Ownership
2012
Year founded
5
Employees
Westport, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Kansas City, US

Produtos e/ou serviços de Intensity Therapeutics

  • INT230-6, a lead product designed for direct injection into solid tumors to cause cancer cell death and immune system activation.
  • Research collaborations with Merck and Bristol-Myers Squibb to test the combination of INT230-6 with key immunotherapies, aiming to improve cancer treatment outcomes.
  • Development of drug delivery technologies focusing on direct tumor injection, aiming to minimize systemic exposure and side effects.
  • Pipeline expansion efforts to include novel drug candidates for various types of cancer, leveraging their proprietary drug formulation technology.
  • Investigation of INT230-6's mechanism of action to inform the development of next-generation cancer therapies and potentially broaden its applicability.

equipe executiva do Intensity Therapeutics

  • Mr. Lewis H. Bender M.A., M.B.A., M.S.Founder, President, CEO & Chairman of the Board
  • Mr. Joseph Talamo CPA, M.B.A.Chief Financial Officer
  • Mr. John Wesolowski CPA, M.B.A.Principal Accounting Officer & Controller
  • Mr. James M. AhlersExecutive Vice President of Corporate Finance

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.